This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Pennant Group, Inc. (PNTG) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
The Pennant Group (PNTG) delivered earnings and revenue surprises of 11.11% and 7.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes The Pennant Group, Inc. (PNTG) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Tenet Healthcare (THC) Soars 76% in a Year: What Lies Ahead?
by Zacks Equity Research
Tenet Healthcare (THC) remains well-poised for growth on increased admissions and surgeries in the Hospital segment, acquisitions, debt repayment efforts and solid operating cash flows.
Humana (HUM), DUOS Unveil Program to Improve Veterans' Health
by Zacks Equity Research
Humana (HUM) collaborates with DUOS to develop a program that aims to provide personalized care and assure the well-being of Louisiana's Veteran community, who have a HUM MA plan and suffer from chronic conditions.
Here's Why The Pennant Group, Inc. (PNTG) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does The Pennant Group, Inc. (PNTG) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes The Pennant Group, Inc. (PNTG) a New Buy Stock
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The Pennant Group, Inc. (PNTG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for The Pennant Group, Inc. (PNTG) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ahead of The Pennant Group, Inc. (PNTG) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of The Pennant Group, Inc. (PNTG) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.47% and 1.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Pennant Group, Inc. (PNTG) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Take the Zacks Approach to Beat the Market: Annexon, NVIDIA, Intuit in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Are Investors Undervaluing The Pennant Group (PNTG) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The Pennant Group, Inc. (PNTG) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
The Pennant Group, Inc. (PNTG) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.
Should Value Investors Buy The Pennant Group (PNTG) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Fast-paced Momentum Stock The Pennant Group, Inc. (PNTG) Is Still Trading at a Bargain
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, The Pennant Group, Inc. (PNTG) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's What Key Metrics Tell Us About The Pennant Group, Inc. (PNTG) Q3 Earnings
by Zacks Equity Research
The headline numbers for The Pennant Group, Inc. (PNTG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.